Diros offers radiofrequency products to treat chronic pain conditions. Credit: TB studio / Shutterstock.com.

Avanos Medical has signed a definitive agreement to acquire Canadian company Diros Technology for an undisclosed sum.

Diros is engaged in the manufacturing of radiofrequency (RF) products that are used for the treatment of chronic pain conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company markets its several products, including RF generators, cannulae and tined probe technology, under the Trident brand.

For chronic pain management, Diros’ products use minimally invasive probes, which heat the nervous tissue near the tip of the probe, to deliver RF energy. This helps deactivate the nerve’s potential to transmit pain signals.

Diros’ RF Trident technology complements Avanos’ COOLIEF-cooled radiofrequency product offering besides enabling it to expand the pain management treatment options.

Avanos CEO Joe Woody said: “The acquisition of Diros Technology strengthens Avanos’ leadership position in RF technology by providing a full range of high-quality, differentiated pain management products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We expect our enhanced portfolio will offer significant opportunities to deliver non-opioid-based, minimally invasive treatments to patients throughout the world.

“With this comprehensive suite of RF offerings, we believe Avanos is poised for future growth across all major sites of patient care: hospitals, ambulatory surgery centres and physician’s offices.”

Avanos intends to finance the deal using funds from its existing credit facility and available cash and subject to customary closing conditions, the deal is anticipated to complete in the third quarter of this year.